Secondary Safety End Points
(Safety Set)

	MVA-BN-RSV (N=9389, N*=9247) n (%)	Placebo (N=8959, N*=8829) n (%)
Serious Adverse Events (Onset at Any Time during the Trial)		
Number of Participants With Serious Adverse Events	517 (5.5)	422 (4.7)
Unsolicited Adverse Events (Onset within 29 days after vaccination)		
Number of Participants With Adverse Events	607 (6.5)	581 (6.5)
Number of Participants With Grade 3 or Higher Adverse Events	11 (0.1)	2 (<0.05)
Solicited Local Adverse Events (Onset within 8 days after vaccination)		
Pain	5704 (61.7)	667 (7.6)
Erythema	522 (5.6)	157 (1.8)
Swelling	448 (4.8)	78 (0.9)
Induration	417 (4.5)	74 (0.8)
Pruritus	1718 (18.6)	470 (5.3)
Solicited Systemic Adverse Events (Onset within 8 days after vaccination)		
Pyrexia	550 (5.9)	309 (3.5)
Headache	3144 (34.0)	1737 (19.7)
Myalgia	4558 (49.3)	1480 (16.8)
Chills	1531 (16.6)	490 (5.5)
Nausea	990 (10.7)	551 (6.2)
Fatigue	3526 (38.1)	1973 (22.3)

N = Number of participants in the safety set
N* = Number of participants with a completed electronic diary
n = Number of participants reporting an event
Percentages are based on N for serious adverse events and unsolicited adverse events and on N* for solicited adverse events